Lercamed

Lercanidipine hydrochloride, the active ingredient in Lercamed, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lercamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used in the management of hypertension, helping to achieve target blood‑pressure levels.

Hypertension: reduces systolic and diastolic pressure in patients with essential hypertension, improving cardiovascular risk profile.

Lercamed may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after the first dose. - Flushing: sensation of warmth and redness, typically on the face or neck. - Peripheral edema: swelling of the ankles or lower legs due to fluid accumulation. - Dizziness or light‑headedness: especially when standing quickly. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Angioedema: rapid swelling of lips, tongue, or airway requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that can cause fainting or shock. - Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis.

Before initiating therapy with Lercamed, clinicians should consider several safety aspects.

Monitor blood pressure: ensure adequate control and avoid excessive lowering. Assess hepatic function: use with caution in patients with liver impairment. Caution in elderly: start at lower doses due to increased sensitivity. Avoid abrupt discontinuation: taper dose to reduce rebound hypertension. Review concomitant CYP3A4 inhibitors: adjust therapy if strong inhibitors are used. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercamed can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug concentration leading to excessive vasodilation. - Co‑administration with other calcium‑channel blockers: additive blood‑pressure lowering effect.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance bradycardia or hypotension. - ACE inhibitors or ARBs: combined effect on blood pressure may require dose adjustment. - Diuretics: can potentiate orthostatic hypotension. - NSAIDs: may reduce antihypertensive efficacy. - Digoxin: increased risk of cardiac conduction disturbances.